Sign In

Mark Tomai

Contract Worker at 3M Healthcare with extensive experience in the Pharmaceutical Industry

Mark Tomai is an accomplished professional in the pharmaceutical industry, currently working as a Contract Worker for Solventum, a company that emerged from 3M Healthcare. He has over 30 years of experience in the field, with a strong focus on drug delivery systems and immunology.

Professional Background

  • Current Role: Tomai has been with Solventum since January 2022, where he continues to leverage his extensive expertise in biopurification and the development of toll-like receptor (TLR) agonists aimed at enhancing drug delivery systems. His work involves significant contributions to vaccine adjuvant development and transdermal drug delivery technologies.1

  • Previous Experience: Before joining Solventum, he spent 12 years as the Head of Vaccine and Microneedle Business Development at 3M Drug Delivery Systems, where he was instrumental in partnering efforts related to transdermal drug delivery and vaccine adjuvants for cancer treatment. His role included licensing TLR agonists to various vaccine companies.1

  • Research Focus: Tomai's research has primarily revolved around immunology, particularly the use of TLR agonists as vaccine adjuvants. He has been involved in numerous projects that enhance immune responses to vaccines, including those targeting COVID-19, HIV, and cancer therapies.23

Education

Tomai holds a Ph.D. in Microbiology/Immunology and a Bachelor of Science in Microbiology, both from the University of Minnesota. His academic background has laid a strong foundation for his innovative contributions to drug discovery and development.1

Contributions and Achievements

  • Publications and Patents: He has authored over 70 peer-reviewed publications and holds 13 issued patents, reflecting his significant contributions to scientific research and innovation within the pharmaceutical sector.1

  • Recognition: Mark Tomai is recognized for his technical expertise and leadership in the industry, often invited to speak at national and international conferences on topics related to immunology and drug delivery systems.1

In summary, Mark Tomai is a prominent figure in the pharmaceutical industry with extensive experience in vaccine development, immunology, and drug delivery systems, currently contributing to advancements at Solventum.

Highlights

An Overview of Vaccine Adjuvants: Current Evidence and Future ...
Distinct TLR adjuvants differentially stimulate systemic and local ...

Related Questions

What specific projects has Mark Tomai worked on at Solventum?
How has Mark Tomai's work at 3M influenced his role at Solventum?
What are some of the notable achievements of Mark Tomai in the pharmaceutical industry?
How does Mark Tomai's expertise in immunology benefit his work at Solventum?
What are toll-like receptor agonists, and how are they used in drug delivery?
Mark Tomai
Mark Tomai, photo 1
Mark Tomai, photo 2
Add to my network

Experience

Contract Worker for 3M Healthcare focusing on 3M's Toll-like receptor agonists, since January 2022
Staff Research Scientist at 3M (1991-Present), Head of Vaccine and Microneedle Business Development at 3M Drug Delivery Systems (2007-Present), Division Scientist at 3M Pharmaceuticals (1991-2005)

Education

Ph.D. in Microbiology Immunology, University of Minnesota (1983-1988); BS in Microbiology, University of Minnesota (1978-1983)

Location

St Paul, Minnesota, United States